Global Endocrine Disorders Market, By Diseases (Addison’s Disease, Gigantism, Goiter, Cushing’s Syndrome, Polycystic Ovary Syndrome (PCOS), Diabetes, Acromegaly, Others), Drug Class (Estrogen, Testosterone, and Progesterone Replacement Therapy), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Endocrine Disorders Market Analysis and Size
The global endocrine disorders market is expected to witness significant growth during the forecast period. The rising diabetic, geriatric, and obese population globally is expected to promote market growth. Advancements in technologies such as the introduction of easy-to-operate test kits facilitated the penetration of home-based diagnosis, which is user-friendly and cost-effective. As per the International Federation, in 2021, around 537 million adults were living with diabetes, and by 2045, this number will increase to 783 million. Increasing diabetes worldwide will lead to increase adoption of insulin hormone testing, thereby projected to boost the market growth.
Data Bridge Market Research analyses a growth rate in the global endocrine disorders market in the forecast period 2022-2029. The expected CAGR of global endocrine disorders market is tend to be around 7.4% in the mentioned forecast period. The market was valued at USD 10.28 billion in 2021, and it would grow upto USD 18.2 billion by 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Endocrine Disorders Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Diseases (Addison’s Disease, Gigantism, Goiter, Cushing’s Syndrome, Polycystic Ovary Syndrome (PCOS), Diabetes, Acromegaly, Others), Drug Class (Estrogen, Testosterone, and Progesterone Replacement Therapy), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V (U.S.), Johnsons & Johnsons Services Inc (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Lilly (U.S.), Merck & Co., Inc. (U.S.), Aurobindo Pharma (India), Bristol-Myers Squibb Company (U.S.), GSK plc (U.K.), Ascendis Pharma A/S (Denmark)
Endocrine disorders are a chronic condition of endocrine glands and hormones in the body. Hormone therapy is the kind of therapy which is widely used in the treatment of endocrine diseases. It works either as replacement or replenishes the deficient hormones and causes the diseases. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Global Endocrine Disorders Market Dynamics
- Increased Incidence of Parathyroid Disorders
Thyroid Disorders, mainly hyperthyroidism, affect 200 million people worldwide; in most countries, half of the population remains undiagnosed. This condition is more predominant among women and the elderly. Increase in the occurrence of parathyroid diseases is anticipated to boost the growth of the global parathyroid disease treatment market. In a recent study, it was stated that between 2003 and 2017, it is projected that 13,897 admissions corresponding to 12,903 patients registered with parathyroid gland disorder were stated in Spain. According to the reports of Informa U.K. Limited, primary hyperparathyroidism (pHPT) is the third most common endocrine disorder. This boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
- Increase in Elderly Population
Rise in elderly population is projected to boost the market size. Parathyroid problems are more common in younger adults between the age group of 30 to 40 years and older people. Thus, an increase in the elderly population will likely create opportunities for the global market growth. As per the article published in journal of the Endocrine Society, a retrospective survey was conducted from January 1997 to June 2018, which projected that 462 patients were diagnosed with primary hyperparathyroidism and 212 were aged above 65.
- Increased Research Activities
Focus on R&D by major market players is projected to drive the global parathyroid disease treatment market. For instance, in June 2017, Amgen, Inc. received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Marketing Authorization of a pediatric formulation, Mimpara (cinacalcet), for children aged three years and above having secondary hyperparathyroidism (HPT). Thus, these policies drive the market growth.
- Product Recall by FDA
The product recall by the Food and Drug Administration (FDA) likely hinders the growth of the global parathyroid disease treatment market. For instance, in September 2019, the Takeda Pharmaceutical Company Limited issued the U.S. recall of NATPARA. The recall is because of a potential issue associated with rubber particulates rising from the rubber septum of the NATPARA cartridge.
- Limiting Adoption of Hormonal Therapy
In most cases, oral medications are considered gold treatment for hypoparathyroidism. This restricts the adoption of available hormonal therapy. Additionally, long-term beneficial drug usage symptoms have still not been revealed across clinical trials, which might limit therapy adoption in patients. According to the Drug literature review 2018, therapy with rhPTH (1-84) is a long-term management option, where more long-term efficacy and safety data are needed in humans. Thus, it restricts the growth of the market.
This global endocrine disorders market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global endocrine disorders market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Endocrine Disorders Market Scope
The global endocrine disorders market is segmented on the basis of treatment, drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Addison’s Disease
- Cushing’s Syndrome
- Polycystic Ovary Syndrome (PCOS)
- Progesterone Replacement Therapy
Route of Administration
- Speciality Centres
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Endocrine Disorders Market Regional Analysis/Insights
The global endocrine disorders market is analyzed and market size insights and trends are provided by treatment, drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global endocrine disorders market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the high income of the countries, high prevalence of parathyroid diseases and advanced healthcare facilities.
Asia-Pacific dominates the market due to the increase’s cases of cardiovascular diseases and rapidly aging population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Endocrine Disorders Market Share Analysis
The global endocrine disorders market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global endocrine disorders market.
Key players operating in the global endocrine disorders market include:
- Teva Pharmaceutical Industries Ltd (Israel)
- Mylan N.V (U.S.)
- Johnsons & Johnsons Services Inc (U.S.)
- F. Hoffman-La Roche Ltd. (Switzerland)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Aurobindo Pharma (India)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc (U.K.)
- Ascendis Pharma A/S (Denmark)